Results 151 to 160 of about 554,589 (315)

Dopamine Agonist-Resistant Microprolactinoma-Mechanisms, Predictors and Management: A Case Report and Literature Review. [PDF]

J Clin Med, 2022
Szmygin H, Szydełko J, Matyjaszek-Matuszek B.   +2 more
europepmc   +1 more source

Chronic exposure to dopamine agonists affects the integrity of striatal D2 receptors in Parkinson's patients

NeuroImage: Clinical, 2017
We aimed to investigate the integrity and clinical relevance of striatal dopamine receptor type-2 (D2R) availability in Parkinson's disease (PD) patients. We studied 68 PD patients, spanning from early to advanced disease stages, and 12 healthy controls.
Marios Politis, Heather Wilson, Kit Wu, David J. Brooks, Paola Piccini   +4 more
doaj  

Terguride—a new dopamine agonist drug: a comparison of its neuroendocrine and side effect profile with bromocriptine

, 1988
E. Ciccarelli, R. Touzel, Michael Besser, A. Grossman   +3 more
openalex   +1 more source

Ropinirole: A dopamine agonist for the treatment of Parkinson’s disease [PDF]

, 1999
Mary D. Kuzel
openalex   +1 more source

Anosmia and Upper Limb Rigidity—A Potential Phenotype of Idiopathic Normal Pressure Hydrocephalus with Cerebrospinal Fluid α‐Synuclein Seeds

Movement Disorders, EarlyView.
Abstract Background The pathophysiology of idiopathic normal pressure hydrocephalus (iNPH) and its association with neurodegenerative disorders is poorly understood. Objectives The aim was to determine the prevalence of α‐synuclein pathology in iNPH and its associations with clinical characteristics. Methods We used α‐synuclein seed amplification assay
Sandrina Weber, Carly M. Farris, Yihua Ma, Mohammed Dakna, Maritta Starke, Sebastian Schade, Michael Bartl, Claudia Trenkwalder, Luis Concha‐Marambio, Brit Mollenhauer   +9 more
wiley   +1 more source

Expanding the spectrum of KCNJ6‐related disorders: Milder phenotype with pathological startle responses

Clinical Genetics, Volume 103, Issue 1, Page 103-108, January 2023., 2023
We describe here the case of a 36‐year‐old female with a de novo pathogenic variant in KCNJ6 (NM_002240.5: c.460G>T; p.(Gly154Cys)) presenting with mild intellectual disability, subtle dysmorphic features, obsessive–compulsive disorder, and an exaggerated startle response, thereby expanding the spectrum of KCNJ6‐related disorders to milder phenotypes ...
Vesna Marija van Midden, Lisa Kinsley, Avram Fraint, Dimitri Krainc, Niccolò E. Mencacci   +4 more
wiley   +1 more source

No Dopamine Agonist Modulation of Brain [¹⁸F]FEOBV Binding in Parkinson's Disease. [PDF]

Mol Pharm, 2022
Albin RL, Kanel P, van Laar T, van der Zee S, Roytman S, Koeppe RA, Scott PJH, Bohnen NI.   +7 more
europepmc   +1 more source

Unsettling the Hegemony of Intention: Agonistic Image Generation [PDF]

arXiv
Current image generation paradigms prioritize actualizing user intention - "see what you intend" - but often neglect the sociopolitical dimensions of this process. However, it is increasingly evident that image generation is political, contributing to broader social struggles over visual meaning.
arxiv  

The agonist activities of the putative antipsychotic agents, L‐745,870 and U‐101958 in HEK293 cells expressing the human dopamine D_4.4 receptor [PDF]

, 1998
Lucien Gazi, Ionel Bobirnac, M Danzeisen, E. Schüpbach, Anne T. Bruinvels, Sabine Geisse, Bernd Sommer, Daniël Hoyer, Mark D. Tricklebank, Philippe Schoeffter   +9 more
openalex   +1 more source

Cognitive and Psychiatric Adverse Effects of Foslevodopa/Foscarbidopa in Patients with Parkinson's Disease

Movement Disorders Clinical Practice, EarlyView.
Sacha Brohée, Emmanuel Roze, David Grabli, Hélène Letrillart, Lise Mantisi, Cendrine Foucard, Elodie Hainque, Florence Cormier, Aurélie Méneret, Fabien Hauw   +9 more
wiley   +1 more source